The Steps From Product Idea to Product Success

Michelangelo once said that his statue of David was embedded in the block of marble and he merely chipped away the edges to reveal it. Is your product idea inside your mind just waiting to come alive? Or, is your product already formed and you need only to smooth out the edges?

Using my Market-Step process your idea will come to life as we progress in the following steps from idea to launch.

TO SELF-MARKET

1. Market Evaluation

2. Concept Evaluation

3. Prototype Creation and Evaluation

4. Patent Decision

5. Planning

6. Development

7. Product Launch

TO SELL OR LICENSE TO A COMPANY

1. Market Evaluation

2. Concept Evaluation

3. Prototype Creation and Evaluation

4. Patent Filing

5. Product Proposal

6. Company Search

7. Negotiate Deal

GETTING STARTED

* Protect Your Idea

When you have an idea, you need to protect it. The first line of defense is to set the date of conception. Start by documenting your idea in an inventor’s notebook, but don’t file a patent until you evaluate its marketability.

MARKET RESEARCH AND EVALUATION

* STEP 1: Market Evaluation

Start the Market-Step process by evaluating the marketability of your invention. With a quick evaluation of the market, you screen out bad ideas before wasting time and money. Your invention is marketable when it solves a problem, meets a need or want, overcomes competition (products and patents), and generates a profit.

* STEP 2: Concept Evaluation

The second step of the Market-Step process is to determine if people like your invention concept. A concept evaluation is an easy-to-use survey method you can create yourself. The results provide you with valuable feedback so you have a better feel whether to proceed with your invention. In addition, a concept evaluation allows people an opportunity to provide helpful suggestions and advice.

* STEP 3: Prototype Evaluation

The third step is to create a prototype and have an evaluation. A prototype can be a physical model, detailed drawing, or animation. With a prototype, you obtain opinions to make sure you’re on the right track. In addition, a prototype evaluation helps you uncover any necessary feature changes before moving onto the next stage.

Marketable? After each of the first three steps, you need to review the evaluation results to determine if your invention is marketable. If results are encouraging, advance to the next step. If results are mixed, you might need to go back and revise your idea and re-test. If results are discouraging, revise the invention or cancel the project entirely to save yourself time and money and move on to your next idea.

GOING FORWARD

Now that you have an overview of the steps, my book Product Idea to Product Success takes you through the details of the Market-Step process, one step at a time.

Whole Slide Scanner At No Upfront Cost

OptraSCAN is a leading end-to-end digital pathology solution provider has launched On-Demand digital pathology business model in England to strengthen the adoption of digital pathology. Pathology labs, healthcare networks, and hospitals can effortlessly adopt digital pathology solutions without any upfront cost and at affordable pricing solutions.

OptraSCAN support laboratories arrive at the optimal configuration of slide scanning instruments required to process efficiently their case throughput. We also offer an On-Demand business model to ensure the most compelling approach possible to financing digitization.

The seamless integration of OptraSCAN provides:

Walk away automation
Slides are scanned in less than a minute at 40x equivalent
Cloud-based whole slide imaging systems
Well-equipped for confocal, brightfield, fluorescence, and frozen section applications
Integrated image management and viewing
Real-time and remote viewing & collaboration
Quantitative and reproducible image analysis

The whole slide scanners that are available with this model are brightfield scanners – OS-Ultra, OS-15, and fluorescence scanners – OS-FL and OS-FLi.

OS-Ultra is a high-speed whole slide digital pathology scanner that scans tissues/cells of size 15×15 mm area at 40x equivalent in less than 60 seconds. OS-Ultra features a unique no-touch slide loading mechanism to diminish workflow errors and produce high-resolution images. The high-speed scanner comes with solutions – IMAGEPath®, the Image Management System apt for viewing, storing and archiving, and TELEPath®, Telepathology software used for real-time, and remote consultations.

Features:

Slide capacity – 80, 160, 320, and 480 slides
Continual slide loading capacity
Slides scanned at 0.25 microns per pixel (the equivalent of 40x)
Scanning time is less than a minute for 15×15 mm region
Patented composite imaging for cytology samples
Images generated up to 0.1 microns per pixel (the equivalent of 80x)
OS-Ultra high-speed whole slide scanner with Noiseless operation
Storage
Local
Cloud

Cytology Image analysis
Morphology tools for Breast and Prostate
IHC biomarker panel for ER/ PR / Her2neu / Ki67 / P53 / EGFR
PD-L1
OS-15 Histopathology and H&E Brightfield Scanners are cloud-enabled to provide the ultimate flexibility for storing, archiving, and managing digital images and metadata. This small footprint, low throughput scanners are lightweight and easily fit into small workspaces. Whole slide scanning is now convenient with high-resolution imaging. OptraSCAN’s Cloud-enabled solutions such as IMAGEPath®, the Image Management System apt for viewing, storing, and archiving as well as TELEPath®, Telepathology software used for real-time, remote consultations are included with OS-15 scanners.

Features:

Cloud-enabled 15-slide Brightfield
Desktop Scanning
20x & 40x magnification
Small footprint

OptraSCAN’s digital pathology scanners are easy to implement and can be integrated in any existing HIS and LIS.

This solution will further assist pathologists and cytologists to adopt digital pathology solutions in the UK.

Benefits of OptraSCAN’s Digital Pathology Solutions?

Provides the pathologist community much-needed flexible working model with a minimum upfront investment
Enables users to focus on their core areas of working without any technological and operational burdens
Supports easy scalability & integration within the user’s existing eco-system
Augments efficient workflows for multi-site collaboration, anytime & anywhere access
Allows integrated real-time remote connectivity for expert opinions & consultations
Offers great opportunities for education, research and supervision opine

What is Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis?

DelveInsight’s “Antibody Drug Conjugate- Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Antibody Drug Conjugate, historical and forecasted epidemiology as well as the Antibody Drug Conjugate market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

What is Antibody Drug Conjugate Market Report?

The Antibody Drug Conjugate market report provides current treatment practices, emerging drugs, Antibody Drug Conjugate market share of the individual therapies, current and forecasted Antibody Drug Conjugate market Size from 2018 to 2030 segmented by seven major markets. The Report also covers current Antibody Drug Conjugate treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Antibody Drug Conjugate Disease Understanding and Treatment Algorithm

The DelveInsight Antibody Drug Conjugate market report gives a thorough understanding of the Antibody Drug Conjugate by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Antibody Drug Conjugate.

Treatment

It covers the details of conventional and current medical therapies available in the Antibody Drug Conjugate market for the treatment of the condition. It also provides Antibody Drug Conjugate treatment algorithms and guidelines in the United States, Europe, and Japan.

Antibody Drug Conjugate Epidemiology

The Antibody Drug Conjugate epidemiology division provide insights about historical and current Antibody Drug Conjugate patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Antibody Drug Conjugate epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Antibody Drug Conjugate Epidemiology

The epidemiology segment also provides the Antibody Drug Conjugate epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Antibody-Drug Conjugate Drug Chapters

Drug chapter segment of the Antibody Drug Conjugate report encloses the detailed analysis of Antibody Drug Conjugate marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Antibody Drug Conjugate clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Antibody Drug Conjugate treatment.

Antibody-Drug Conjugate Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Antibody Drug Conjugate treatment.

Antibody Drug Conjugate Market Outlook

The Antibody Drug Conjugate market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Antibody Drug Conjugate market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Antibody Drug Conjugate market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Antibody Drug Conjugate Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Antibody Drug Conjugate market or expected to get launched in the market during the study period 2018-2030. The analysis covers Antibody Drug Conjugate market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Antibody Drug Conjugate Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Antibody Drug Conjugate key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Antibody Drug Conjugate emerging therapies.

Reimbursement Scenario in Antibody Drug Conjugate

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Antibody Drug Conjugate domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Antibody Drug Conjugate market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Antibody Drug Conjugate Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.